Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 16, 2019. The document serves as a transaction notification regarding a specific corporate action involving the company's Performance Share Plan.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It reports solely on a specific share transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of Ordinary Shares via dividend re-investment.
- Transaction Date: April 12, 2019.
- Transaction Price: £15.6560 per share.
- Total Volume: 4,618.605 shares.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It details a routine administrative transaction where dividends paid on April 11, 2019, were re-invested to acquire shares for the Performance Share Plan, subject to a 2-year holding period.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. The only noted condition is the 2-year holding period applicable to the shares acquired through the dividend re-investment plan.
Investor Verification Points
- Verify the total number of shares acquired (4,618.605) and the execution price (£15.6560) against the London Stock Exchange records for April 12, 2019.
- Confirm the identity of the Executive Director involved (Mr. S P Dingemans) and the specific terms of the Performance Share Plan.
- Note that this filing does not contain quarterly or annual financial results; investors should refer to the company's Form 20-F or interim reports for financial performance data.